Isotope technology firm Eckert & Ziegler has agreed to supply lutetium-177 (Lu-177) to the Canadian biotechnology firm Alpha-9 Theranostics for use in clinical trials.
Alpha-9 will use the radioisotope in the clinical trials for its therapeutic candidates for solid and hematologic malignancies. Targeted radionuclide therapy with Lu-177, which is currently under late-stage clinical development for several types of cancer, may provide an alternative treatment option in the field of precision oncology.
